The financials
Haemonetics Corporation by the numbers
Haemonetics Corporation (HAE) reported revenue of $346M in Q4 2026 (quarter ended March 28, 2026), up 4.8% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $20M. For the full year FY2026, revenue was $1.33B (−2.0% year on year) and net income $97M. Its largest segment in 2025-Q4 was Plasma at $139M, 41% of the disclosed total, just ahead of Hemostasis Management Hospital at 26%.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $346M | $331M | +4.8% |
| Gross profit | $198M | $193M | +2.7% |
| Operating income | −$23M | $71M | to a loss |
| Net income | −$20M | $58M | to a loss |
| Diluted EPS | −$0.41 | $1.17 | to a loss |
| Operating | Revenue | Share |
|---|---|---|
| Plasma | $139M | 41% |
| Hemostasis Management Hospital | $87M | 26% |
| Blood Center | $57M | 17% |
| Interventional Technologies Hospital | $56M | 17% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q4 2025Total $339.0M (+3.4%)
Hemostasis Management Hospital grew +8.3% year on yearWhole Blood Blood Center -100% year on year
Segment Latestquarter on quarteryear on year
- Plasma$138.9M$138.9MQoQ +11%year on year +3.5%+11%+3.5%
- Hemostasis Management Hospital$87.4M$87.4MQoQ +1.2%year on year +8.3%+1.2%+8.3%
- Blood Center$56.6M$56.6MQoQ +0.19%year on year -20%+0.19%-20%
- Interventional Technologies Hospital$56.1M$56.1MQoQ -5.1%year on year -11%-5.1%-11%
- Whole Blood Blood Center$0.00$0.00QoQ -100%year on year -100%-100%-100%